MARS therapy in critically ill patients with advanced malignancy: A clinical and technical report

Liver International

Volumn 23, Issue SUPPL. 3, 2003, Pages 52-60

  Tan, Han Khim ^a   Lim, J S S ^a   Tan, C K ^a   Ng, H S ^a   Chow, P ^a   Lui, H F ^a   Wong, G C ^a   Tan, P H C ^a   Raghuram, J ^a   Ng, H N ^a   Choong, L H L ^a   Wong, K S ^a   Woo, K T ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Acute liver failure (ALF); Bone marrow transplant (BMT); Hepatocellular carcinoma (HCC); Leukaemia; Liver resection; Lymphoma; MARS clearance limits

Indexed keywords

ALBUMIN; AMMONIA; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BILIRUBIN; CREATININE; CYCLOSPORIN A; GANCICLOVIR; HEPARIN; INOTROPIC AGENT; LACTIC ACID; METHYLPREDNISOLONE; METICILLIN; OKT 3; OXYGEN; UREA; URSODEOXYCHOLIC ACID;

ACUTE KIDNEY FAILURE; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ADVANCED CANCER; AMMONIA BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; BLEEDING; BLOOD CLOTTING; BONE MARROW TRANSPLANTATION; BUDD CHIARI SYNDROME; CANCER CHEMOTHERAPY; CASE REPORT; CLINICAL STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CRITICAL ILLNESS; CYTOMEGALOVIRUS INFECTION; DEATH; DIALYSATE; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG SAFETY; FEMALE; GENDER; GENERAL HOSPITAL; HEMODIALYSIS; HEMOFILTRATION; HEMOLYTIC UREMIC SYNDROME; HEPATITIS B; HODGKIN DISEASE; HOSPITAL INFECTION; HUMAN; HUMAN TISSUE; INTENSIVE CARE UNIT; LACTATE BLOOD LEVEL; LIVER CELL CARCINOMA; LIVER FAILURE; LOW DRUG DOSE; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PARTIAL HEPATECTOMY; PNEUMONIA; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRESSURE MEASUREMENT; PROTHROMBIN TIME; RECURRENT CANCER; REOPERATION; SEPSIS; SINGAPORE; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE COUNT; THROMBOSIS; TIME; TREATMENT OUTCOME; ULTRAFILTRATION; UREA BLOOD LEVEL; UREMIA; VEIN OCCLUSION; VIRUS HEPATITIS;

EID: 10744229946     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1478-3231.23.s.3.3.x     Document Type: Article

References (27)

1. Larsen F S, Hansen B A, Blei A T. Intensive care management of patients with acute liver failure with emphasis on systemic hemodynamic instability and cerebral edema: a critical appraisal of pathophysiology. Can J Gastroentrol 2000; 14: 105D-11D.
2. Mitzner S R, Stange J, Peszynski P, Klammt S. Extracorporeal support of the failing liver. Curr Opin Crit Care 2002; 8: 171-7.
3. Ash S R, Caldwell C A, Singer G G, et al. Treatment of acetaminophen-induced hepatitis and fulminant hepatic failure with extracorporeal sorbent-based devices. Adv Ren Replace Ther 2002; 9: 42-53.
4. Sen S, Felldin M, Steiner C, et al. Albumin dialysis and Molecular Adsorbents Recirculating System (MARS) for acute Wilson's disease. Liver Transpl 2002; 8: 962-7.
5. Kellersmann R, Gassel H J, Buhler C, et al. Application of Molecular Adsorbent Recirculating System (MARS) in patients with severe liver failure after hepatic resection or transplantation: initial single-centre experiences. Liver 2002; 22: 56-8.
6. Steiner C, Mitzner S. Experiences with MARS liver support therapy in liver failure: analysis of 176 patients of the international MARS registry. Liver 2002; 22: 20-5.
7. Heemann U, Treichel U, Loock J, et al. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 2002; 36: 949-58.
8. Mitzner S R, Stange J, Klammt S, et al. Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure. J Am Soc Nephrol 2001; 12: S75-82.
9. Jalan R, Williams R. Improvement in cerebral perfusion after MARS therapy: further clues about the pathogenesis of hepatic encephalopathy. Liver Transpl 2001; 7: 713-5.
10. Schmidt L E, Svendsen L B, Sorensen V R, et al. Cerebral blood flow velocity increases during a single treatment with the molecular adsorbents recirculating system in patients with acute-on-chronic liver failure. Liver Transpl 2001; 7: 709-12.
11. Awad S S, Swaniker F, Magee J, et al. Results of a phase I trial evaluating a liver support device utilizing albumin dialysis. Surgery 2001; 130: 354-62.
12. Mitzner S R, Klammt S, Peszynski P, et al. Improvement of multiple organ functions in hepatorenal syndrome during albumin dialysis with the molecular adsorbent recirculating system. Ther Apher 2001; 5: 417-22.
13. Kreymann B, Seige M, Schweigart U, et al. Albumin dialysis: effective removal of copper in a patient with fulminant Wilson disease and successful bridging to liver transplantation: a new possibility for the elimination of protein-bound toxins. J Hepatol 1999; 31: 1080-5.
14. Wyke R J, Canalese J C, Gimson A E, Williams R. Bacteraemia in patients with fulminant hepatic failure. Liver 1982; 2: 45-52.
15. Strauss G, Hansen B A, Kirkegaard P, et al. Liver function, cerebral blood flow autoregulation and hepatic encephalopathy in fulminant hepatic failure. Hepatology 1997; 25: 837-9.
16. De Rave S, Tilanus H W, Van Der Linden J, et al. The importance of orthotopic liver transplantation in acute hepatic failure. Transpl Int 2002; 15: 29-33.
17. Lo C M, Fan S T, Liu C L, et al. Ten-year experience with liver transplantation at Queen Mary Hospital: retrospective study. Hong Kong Med J 2002; 8: 240-4.
18. Jalan R, Williams R. Acute-on-chronic liver failure. Pathophysiological basis of therapeutic options. Blood Purif 2002; 20: 252-61.
19. Mann D V, Lam W W, Hjelm N M, et al. Human liver regeneration: hepatic energy economy is less efficient when the organ is diseased. Hepatology 2001; 34: 557-65.
20. Redaelli C A, Wagner M, Krahenbuhl L, et al. Liver surgery in the era of tissue-preserving resections: early and late outcome in patients with primary and secondary hepatic tumors. World J Surg 2002; 26: 1126-32.
21. Mitzner S, Stange J, Klammt S, et al. Albumin dialysis using the molecular adsorbent recirculating system. Curr Opin Nephrol Hypertens 2001; 10: 1-7.
22. Ronco C, Bellomo R. Acute renal failure and multiple organ dysfunction in the ICU: from renal replacement therapy (RRT) to multiple organ support therapy (MOST). Int J Artif Organs 2002; 25: 733-47.
23. Arai T, Yoshikai Y, Kamiya J, et al. Bilirubin impairs bactericidal activity of neutrophils through an antioxidant mechanism in vitro. J Surg Res 2001; 96: 107-13.
24. Gettings L G, Reynolds H N, Scalea T. Outcome in post-traumatic acute renal failure when continuous renal replacement therapy is applied early vs late. Intensive Care Med 1999; 25: 805-13.
25. Ronco C, Bellomo R, Homel P, et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 2000; 356: 26-30.
26. Tan H K, Baldwin I, Bellomo R. Continuous venovenous haemofiltration without anticoagulation in high-risk patients. Intensive Care Med 2000; 26: 1652-7.
27. McIntyre C W, Fluck R J, Freeman J G, Lambie S H. Characterization of treatment dose delivered by albumin dialysis in the treatment of acute renal failure associated with severe hepatic dysfunction. Clin Nephrol 2002; 58: 376-83.